Cardiopulmonary Effects of Bronchoalveolar Wash on Patients With Acute Respiratory Distress Syndrome (FLOOD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Limoges, France, 87042
- Limoges University hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients older than 18 years
- Patients intubated mechanically ventilated
- Patients with ARDS according to the new definition of Berlin
- Patients under sedation / analgesia
- Patients for whom BAL is programmed
- Collection of non-family opposition
Exclusion Criteria:
- PaO2 / FiO2 <50 or any situation which according to investigator would create a risk to the patient during the procedure
- Persistent hypotension despite the administered therapeutic
- Patients tracheotomy
- Patients dying
- Care limitations Patients
- Known allergy to muscle relaxants
- Pregnant woman
- Patients under guardianship or under judicial protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bronchoalveolar Lavage
BAL was performed in accordance with current practice.
Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure.
Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor.
O2 saturation (SpO2) is monitored continuously by pulse oximetry.
|
BAL was performed in accordance with current practice.
Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure.
Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor.
O2 saturation (SpO2) is monitored continuously by pulse oximetry.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in PaO2/FiO2 measurement
Time Frame: Baseline and 10 minutes
|
Assessment of the change in PaO2/FiO2 in immediate post BAL compared to pre BAL results
|
Baseline and 10 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: VIGNON Philippe, MD, University Hospital, Limoges
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Dimercaprol
Other Study ID Numbers
Other Study ID Numbers
- I14033 FLOOD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.